FDA De Novo Classification: The Special Controls You Write Become Everyone Else's Predicate

Grant a De Novo classification request and FDA does more than clear your device for the U.S. market. It issues a written order that creates a new device classification — a regulation, codified in 21 CFR Part 860 — and writes the special controls you proposed directly into it. Most teams treat the special controls section of a De Novo request as the part you draft to satisfy the reviewer. It is actually the part that defines the compliance bar for the entire product code, starting with your own next design change.

What a De Novo grant actually does

Section 513(f)(2) of the FD&C Act exists for a specific gap: a device with no legally marketed predicate is automatically placed into Class III under 513(f)(1), which normally means a Premarket Approval application. De Novo lets a sponsor ask FDA to instead classify the device into Class I or Class II, where general controls — or general controls plus special controls — can provide reasonable assurance of safety and effectiveness without the PMA burden. FDA's 2021 final rule codified the procedures for that request at 21 CFR Part 860, Subpart D, effective January 3, 2022. The rule did not change the underlying statute; it gave the process the same procedural footing 510(k) and PMA have long had.

The special controls are the deliverable, not a formality

A De Novo request has to do more than argue that general controls alone are insufficient. When a sponsor proposes special controls to close that gap, FDA's own 21 CFR Part 860 framework expects a complete discussion of why those controls, together with general controls, provide reasonable assurance of safety and effectiveness for the device's intended use — not a restated risk list. Teams that treat this section as boilerplate, borrowed from a related product's labeling requirements or a generic performance-testing paragraph, are writing a request FDA has to send back on deficiency. Teams that treat it as the actual regulation they are asking FDA to publish get a classification order that matches what they can defend in practice.

• The no-predicate finding. A documented basis for why the device is automatically Class III under 513(f)(1) — no legally marketed device of the same type and intended use.
• The classification rationale. The case under 513(a)(1) for Class I or Class II: why general controls, or general and special controls, are sufficient without a PMA.
• The special controls themselves, with supporting data. Each proposed control — performance testing, labeling requirements, biocompatibility, software documentation — justified with the evidence FDA needs to adopt it into the classification regulation.
• The benefit-risk analysis. A demonstration that the probable benefits to health outweigh the probable risks for the intended patient population and use conditions.

A De Novo request is not a form you fill out to clear one device. It is a draft regulation FDA is deciding whether to publish — and you are the one writing it. Why special controls drafting is not a late-stage task

Your device becomes the whole category's predicate

The consequence sponsors underweight is what happens after the order issues. Once FDA classifies the device type into Class I or Class II, that device becomes eligible to serve as a predicate for future 510(k) submissions of the same type — and nothing in the statute limits that to the original requester. A competitor can build a device to the same intended use, meet the general and special controls your classification order established, and clear FDA through the faster, cheaper 510(k) pathway you were never offered, because no predicate existed when you filed. You absorbed the De Novo cost and timeline to prove the category was viable; the special controls you wrote now set the floor everyone after you has to clear, and the ceiling you cannot quietly exceed without triggering your own new submission. Sponsors who plan for this — deliberately, before the order issues — treat the special controls draft as a competitive document as much as a regulatory one.

None of this argues against De Novo — for a genuinely novel, low-to-moderate-risk device, it remains the only route to Class I or Class II without a PMA. It argues against treating the request as a clearance exercise and discovering the strategic consequences after the classification order publishes. A Breakthrough Devices designation can shape the interactive review that leads into a De Novo submission, but it does not change what the special controls section has to accomplish once you file. If you are heading toward a first-in-category device and have not yet mapped what the classification order will require of your own product roadmap, that is where a De Novo classification strategy engagement earns its cost before the request goes in, not after FDA writes back with questions your own competitors will later benefit from having asked.